CCND1 and neoplasm: Specifically, we and others have previously shown that genetic deletion or pharmacologic inhibition of downstream effectors of β-catenin-TCF/LEF interactions, such as cyclin D1 (encoded by CCND1)57, GS16, mTORC121, TBX317, AXIN258, or TNFRSF1959 either result in partial tumor responses or compensatory negative feedback loops leading to enhanced tumorigenesis.